

Regd. Office and works:

Mhow - Neemuch Road, Sector 1, CIN: L70100MP1983PLC002231
Pithampur - 454775, Dist. Dhar
Madhya Pradesh, India

Ph:- 07292-256205

Fax:- 0731-4041435

E mail:- investors@medicaps.com

Web site:- www.medicaps.com

MCL/SE/2024-2025

Date: 07.08.2024

Online filing at: www.listing.bseindia.com

To,

The General Manager

DCS-CRD

BSE Limited

Phiroze Jeejeebhoy Towers,

Dalal Street Fort, Mumbai – 400001(M.H.)

**SUBJECT: OUTCOME OF BOARD MEETING HELD ON 07TH AUGUST, 2024
PURSUANT TO REGULATION 30 OF SEBI (LISTING OBLIGATIONS AND
DISCLOSURE REQUIREMENTS) REGULATIONS, 2015.**

**REFERENCE: MEDI-CAPS LIMITED (BSE SCRIP CODE: 523144, ISIN:
INE442D01010)**

Dear Sir/Madam,

With reference to the above captioned subject and pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform that, Board of Directors at their meeting held on Wednesday i.e. 07th August, 2024 has inter alia considered and approved the following businesses:

- (1) Un-audited Standalone and Consolidated Financial Results of the Company for the quarter ended on 30th June, 2024 along with Limited Review Report thereon.
- (2) Board's Report on the operations of the Company along with required annexure and Corporate Governance Report and Management Discussion and Analysis Report for the year ended 31st March, 2024.
- (3) Continuation of directorship of Mrs. Kusum Mittal (DIN: 00035356) as the Non-Executive Women Director of the Company on attaining the age of 75 (seventy-five) years.
- (4) Convening of 41st Annual General Meeting (AGM) on Thursday, 26th September, 2024 at 12.30 P.M. (IST) through Video Conferencing (VC) or Other Audio-Visual Means (OAVM).
- (5) Change of Registered Office outside the local limits of city, town or village i.e. from Mhow - Neemuch Road, Sector 1, Pithampur - 454775, Dist. Dhar (M.P.) to 201, Pushpratna Paradise 9/5 New Palasiya, Opposite UCO Bank, Indore (M.P.) 452001 w.e.f. 01st October, 2024 subject to approval of members in ensuing 41st Annual General Meeting.
- (6) Other routine businesses with the permission of chair.

Regd. Office and works:

Mhow - Neemuch Road, Sector 1, CIN: L70100MP1983PLC002231
Pithampur - 454775, Dist. Dhar
Madhya Pradesh, India

Ph:- 07292-256205

Fax:- 0731-4041435

E mail:- investors@medicaps.com

Web site:- www.medicaps.com

Further, copy of Un-Audited Standalone and Consolidated Financial Results shall also be submitted in XBRL mode within 24 hours from the conclusion of Board Meeting.

The aforesaid Un-Audited Standalone and Consolidated Financial Results will be uploaded on the Company's website www.medicaps.com and on the website of the Stock Exchange at www.bseindia.com. Further the extracts of aforesaid results will be published in Hindi (vernacular) and widely circulated English Newspaper.

The Meeting of the Board of Directors commenced at 03:00 P.M. and concluded at 4.00 P.M.

You are requested to please take on record the same.

Thanking You,

Yours Faithfully,

FOR MEDI-CAPS LIMITED

ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321

Encl.: Un-audited Standalone and Consolidated Financial Results along with limited review report for quarter ended 30th June, 2024


LIMITED REVIEW REPORT

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of Medi-Caps Limited (the Company) Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

To,
THE BOARD OF DIRECTORS OF
MEDI-CAPS LIMITED

SCOPE OF THE REVIEW

1. We have reviewed the accompanying statement of unaudited standalone financial results ("the Statement") of MEDI-CAPS LIMITED ("the Company") for the quarter ended 30th June 2024 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended ('SEBI Listing Regulations'), including relevant circulars issued by the SEBI from time to time.
2. The Statement is the responsibility of the Company's Management and has been approved by the Company's Board of Directors. Our responsibility is to issue a report on the Statement based on our review of the Statement, which has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), specified under Section 133 of the Companies Act, 2013 read with relevant rules issued there under, and other accounting principles generally accepted in India and in Compliance with Regulation 33 of the SEBI Listing Regulations.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



CONCLUSION

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the applicable Indian accounting standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date: 07.08.2024


Place: Indore

UDIN: 24429040BKESHS1689

For, Rawka & Associates

(Chartered Accountants)

FRN 021606C



A handwritten signature in blue ink, appearing to read "Venus Rawka".

Venus Rawka

(Partner)

M. No. 429040

MEDI-CAPS LIMITED

CIN: L70100MP1983PLC002231

Regd. Office: Mhow -Neemuch Road, Sector -1, Pithampur - 454775, Dist. Dhar (M.P.)

Website: www.medicaps.com, Email: investors@medicaps.com, Tel: 07292-256205, Fax: 0731-4041435

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2024

(Amount in Lacs except EPS)

S.N.	Particulars	Quarter Ended			Year Ended
		03 Month Ended 30.06.2024	Preceeding 03 Month Ended 31.03.2024	Corresponding 03 Month Ended in the previous year 30.06.2023	Previous Year Ended 31.03.2024
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
I	Revenue from Operation				
	(a) Net sales	27.75	184.29	0.00	693.03
	(b) Other operating income	1.27	12.63	1.77	23.51
	Revenue from Operation	29.02	196.92	1.77	716.54
II	Other Income	10.72	13.69	0.80	14.72
III	Total income (I+II)	39.74	210.61	2.57	731.26
IV	Expenses				
	a) Cost of material consumed	0.00	0.00	0.00	0.00
	b) Purchase of stock in trade	0.00	0.00	0.00	0.00
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.06	0.36	0.00	1.20
	d) Employee benefits expense	45.23	42.27	6.10	82.88
	e) Finance costs	0.00	0.00	0.00	0.00
	f) Depreciation and amortisation expense	4.00	4.00	4.00	16.01
	g) Power Cost	0.07	0.16	0.06	0.43
	h) Freight Exp.	0.00	0.00	0.00	0.00
	i) Other expenses	23.55	49.70	30.63	148.01
	Total Expenses (IV)	72.91	96.49	40.79	248.53
V	Profit/(Loss) before exceptional item & tax (III-IV)	-33.17	114.12	-38.22	482.73
VI	Exceptional items	0.00	0.00	0.00	0.00
VII	Profit/ (Loss) before tax (V-VI)	-33.17	114.12	-38.22	482.73
VIII	Tax expense				
	1) Current Tax	0.00	50.00	0.00	95.00
	2) Earlier year (excess)/Short provision for tax written back	0.00	0.00	0.00	0.00
	3) Deferred Tax	0.00	-1.09	0.00	-1.09
	Total Tax Expenses	0.00	48.91	0.00	93.91
IX	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0.00	0.00	0.00	0.00
X	Profit (Loss) for the period from continuing operations (VII-VIII)	-33.17	65.21	-38.22	388.82
XI	Profit/(loss) from discontinued operations	0.00	0.00	0.00	0.00
XII	Tax expense of discontinued operations	0.00	0.00	0.00	0.00
XIII	Profit/(loss) from Discontinued operations (after tax) (XI-XII)	0.00	0.00	0.00	0.00
XIV	Share of profit (loss) of associates and joint ventures accounted for using equity method	0.00	0.00	0.00	0.00
XV	Profit/(loss) for the period (X+XIII)	-33.17	65.21	-38.22	388.82
XVI	Other comprehensive income				
	(a) (i) items that will not be reclassified to statement of profit & loss	46.46	28.05	30.22	149.36
	(ii) Income tax on items that will not to be reclassified to statement of P& L	0.00	0.00	0.00	0.00
	(b) (i) items that will be reclassified to statement of profit & loss	0.00	0.00	0.00	0.00
	(ii) Income tax on items that will be reclassified to statement of P& L	0.00	0.00	0.00	0.00
	Other comprehensive income :	46.46	28.05	30.22	149.36
XVII	Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	13.29	93.26	-8.00	538.18
XVIII	Profit or Loss Attributable to				
	Profit or Loss Attributable to owners of Parents	0.00	0.00	0.00	0.00
	Profit or Loss Attributable to non-Controlling Interest	0.00	0.00	0.00	0.00

XIX	Total Comprehensive Income for the period Attributable to				
	Total Comprehensive Income for the period Attributable to owners of Parents	0.00	0.00	0.00	0.00
	Total Comprehensive Income for the period Attributable to non-Controlling Interest	0.00	0.00	0.00	0.00
XX	Paid-up equity share capital of the company	1247.00	1247.00	1247.00	1247.00
XXI	Reserve Excluding Revaluation Reserve	0.00	0.00	0.00	5401.93
XXII	Earnings per equity share (for continuing operation)				
	a) Basic (Rs.)	-0.27	0.52	-0.31	3.12
	b) Diluted (Rs.)	-0.27	0.52	-0.31	3.12
XXIII	Earnings per equity share (for discontinued operation)				
	a) Basic (Rs.)	0.00	0.00	0.00	0.00
	b) Diluted (Rs.)	0.00	0.00	0.00	0.00
XXIV	Earnings per equity share (for discontinued and continuing operation)				
	a) Basic (Rs.)	-0.27	0.52	-0.31	3.12
	b) Diluted (Rs.)	-0.27	0.52	-0.31	3.12

DATE: 07.08.2024
PLACE: INDORE

For and on behalf of board of directors of
MEDICAPS LIMITED



ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321


LIMITED REVIEW REPORT

Independent Auditor's Review Report On Consolidated Unaudited Quarterly Financial Results of Medi-Caps Limited (the Parent Company) Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

To,
THE BOARD OF DIRECTORS OF
MEDI-CAPS LIMITED

SCOPE OF THE REVIEW

1. We have reviewed the accompanying Statement of the Consolidated Unaudited Financial Results ("the Statement") of Medi-Caps Limited ("the Parent Company") and its subsidiary (the Parent and its subsidiary together referred to as "the Group"), and its share of the net profit after tax and total comprehensive profit for the quarter ended June 30, 2024, being submitted by the Parent Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the SEBI Listing Regulations'), including relevant circular issued by the SEBI time to time.
2. This Statement, which is the responsibility of the Parent Company's Management and approved by the Parent Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the SEBI Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of its wholly-owned subsidiary **Medgel Private Limited**.

CONCLUSION

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the information and explanations given to us by the Parent Company's Management, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of SEBI- (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The consolidated unaudited financial results include the financial results of Medgel Private Limited (wholly owned subsidiary) which also has been reviewed by us and certified by the management, whose interim consolidated financial results reflect a total income of Rs.634.03 Lakhs, total net loss after tax of Rs. (55.65) Lakhs and total comprehensive income of Rs. 103.96 Lakhs for the quarter ended June 30, 2024 as considered in the consolidated unaudited financial results. According to the information and explanations given to us by the Management, these interim financial statements/ financial information/ financial results are not material to the group.

Our Conclusion on the statement is not modified in respect of the above matter.

Date: 07.08.2024

Place: Indore

UDIN: 24429040BKESHT8233

For, Rawka & Associates
(Chartered Accountants)
FRN 021606C



A handwritten signature in blue ink, appearing to be "Venus Rawka", written over a horizontal line.

Venus Rawka
(Partner)
M. No. 429040

MEDI-CAPS LIMITED

CIN: L70100MP1983PLC002231

Regd. Office: Mhow - Neemuch Road, Sector - 1, Pithampur - 454775, Dist. Dhar (M.P.)

Website: www.medicaps.com Email: investors@medicaps.com, Tel: 07292-256205, Fax: 0731-4041435

UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2024

(Amount in Lacs except EPS)

S.N.	Particulars	Quarter Ended			Year Ended
		03 Month Ended 30.06.2024	Preceeding 03 Month Ended 31.03.2024	Corresponding 03 Month Ended in the previous year 30.06.2023	Previous Year Ended 31.03.2024
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
I	Revenue from Operation				
	(a) Net sales	614.56	741.84	623.64	2656.35
	(b) Other operating income	4.88	45.07	14.06	78.16
	Revenue from Operation	619.44	786.91	637.70	2734.51
II	Other Income	14.59	24.28	6.75	47.50
III	Total income (I+II)	634.03	811.19	644.45	2782.01
IV	Expenses				
	a) Cost of material consumed	390.62	198.85	270.04	842.84
	b) Purchase of stock in trade	0.00	0.00	0.00	0.00
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-184.45	74.31	23.73	108.91
	d) Employee benefits expense	171.77	207.57	179.33	706.88
	e) Finance costs	0.00	0.00	0.00	0.00
	f) Depreciation and amortisation expense	42.57	32.83	45.27	168.65
	g) Power Cost	43.23	37.18	37.91	148.15
	h) Freight Exp.	38.64	58.78	13.90	153.52
	i) Other expenses	187.30	260.57	185.72	777.66
	Total Expenses (IV)	689.68	870.09	755.90	2906.61
V	Profit/(Loss) before exceptional item & tax (III-IV)	-55.65	-58.90	-111.45	-124.60
VI	Exceptional items	0.00	0.00	0.00	0.00
VII	Profit/ (Loss) before tax (V-VI)	-55.65	-58.90	-111.45	-124.60
VIII	Tax expense				
	1) Current Tax	0.00	50.00	0.00	95.00
	2) Earlier year (excess)/Short provision for tax written back	0.00	0.00	0.00	5.56
	3) Deferred Tax	0.00	-1.09	0.00	-1.09
	Total Tax Expenses	0.00	48.91	0.00	99.47
IX	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0.00	0.00	0.00	0.00
X	Profit (Loss) for the period from continuing operations (VII-VIII)	-55.65	-107.81	-111.45	-224.08
XI	Profit/(loss) from discontinued operations	0.00	0.00	0.00	0.00
XII	Tax expense of discontinued operations	0.00	0.00	0.00	0.00
XIII	Profit/(loss) from Discontinued operations (after tax) (XI-XII)	0.00	0.00	0.00	0.00
XIV	Share of profit (loss) of associates and joint ventures accounted for using equity method	0.00	0.00	0.00	0.00
XV	Profit/(loss) for the period (X+XIII)	-55.65	-107.81	-111.45	-224.08
XVI	Other comprehensive income				
	(a) (i) items that will not be reclassified to statement of profit & loss	159.61	100.21	109.82	465.27
	(ii) Income tax on items that will not to be reclassified to statement of P&L	0.00	0.00	0.00	0.00
	(b) (i) items that will be reclassified to statement of profit & loss	0.00	0.00	0.00	0.00
	(ii) Income tax on items that will be reclassified to statement of P&L	0.00	0.00	0.00	0.00
	Other comprehensive income :	159.61	100.21	109.82	465.27
XVII	Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	103.96	-7.60	-1.63	241.20
XVIII	Profit or Loss Attributable to				
	Profit or Loss Attributable to owners of Parents	-55.65	-107.81	-111.45	-224.08
	Profit or Loss Attributable to non-Controlling Interest	0.00	0.00	0.00	0.00

XIX	Total Comprehensive Income for the period Attributable to				
	Total Comprehensive Income for the period Attributable to owners of Parents	103.96	-7.60	-1.63	241.20
	Total Comprehensive Income for the period Attributable to non-Controlling Interest	0.00	0.00	0.00	0.00
XX	Paid-up equity share capital of the company	1247.00	1247.00	1247.00	1247.00
XXI	Reserve Excluding Revaluation Reserve	0.00	0.00	0.00	10851.33
XXII	Earnings per equity share (for continuing operation)				
	a) Basic (Rs.)	-0.45	-0.86	-0.89	-1.80
	b) Diluted (Rs.)	-0.45	-0.86	-0.89	-1.80
XXIII	Earnings per equity share (for discontinued operation)				
	a) Basic (Rs.)	0.00	0.00	0.00	0.00
	b) Diluted (Rs.)	0.00	0.00	0.00	0.00
XXIV	Earnings per equity share (for discontinued and continuing operation)				
	a) Basic (Rs.)	-0.45	-0.86	-0.89	-1.80
	b) Diluted (Rs.)	-0.45	-0.86	-0.89	-1.80

DATE: 07.08.2024
PLACE: INDORE

For and on behalf of board of directors of
MEDI-CAPS LIMITED



ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321

MEDI-CAPS LIMITED

CIN: L70100MP1983PLC002231

Regd. Office: Mhow - Neemuch Road, Sector - 1, Pithampur - 454775, Dist. Dhar (M.P.)

Website: www.medicaps.com Email: investors@medicaps.com, Tel: 07292-256205, Fax: 0731-4041435

UNAUDITED CONSOLIDATED SEGMENTWISE REVENUE, RESULTS AND CAPITAL EMPLOYED FOR THE QUARTER ENDED 30.06.2024

(Amount in Lacs)

S.No.	Segment Revenue	Quarter Ended			Year Ended
		03 Month Ended 30.06.2024	Preceding 03 Month Ended 31.03.2024	Corresponding 03 Month Ended in the previous year 30.06.2023	Previous Year Ended 31.03.2024
		Unaudited	Audited	Unaudited	Audited
1	Segment Revenue				
	Pharma Division	590.42	600.58	641.89	2050.75
	Real Estate Division	29.02	210.61	2.57	731.26
	Other	0.00	0.00	0.00	0.00
	Net Sale/Income From Operations	619.44	811.19	644.45	2782.01
2	Segment Results (Profit) (+)/ Loss (-) before tax and Interest				
	Pharma Division	-22.48	-173.03	-73.21	-607.33
	Real Estate Division	-33.17	114.12	-38.22	482.73
	Other	0.00	0.00	0.00	0.00
	Total	-55.65	-58.90	-111.44	-124.60
	Interest Income	0.00	0.00	0.00	0.00
	Interest Expenses	0.00	0.00	0.01	0.00
	Other Unallocable Expenditure net off	0.00	0.00	0.00	0.00
	Unallocable Income	0.00	0.00	0.00	0.00
	Profit Before Tax	-55.65	-58.90	-111.45	-124.60
3	Capital Employed				
	Segment Assets (A)				
	Pharma Division	6058.94	5919.27	6573.04	5919.27
	Real Estate Division	6728.74	6809.22	6157.87	6809.22
	Other	0.00	0.00	0.00	0.00
	Total (A)	12787.68	12728.49	12730.92	12728.49
	Segment Liabilities (B)				
	Pharma Division	518.86	469.86	820.30	469.86
	Real Estate Division	66.52	160.30	55.12	160.30
	Other	0.00	0.00	0.00	0.00
	Total (B)	585.38	630.16	875.42	630.16
4	Total Capital Employed (Segment Assets-Segment Liabilities)				
	Pharma Division	5540.08	5449.41	5752.75	5449.41
	Real Estate Division	6662.23	6648.92	6102.76	6648.92
	Other	0.00	0.00	0.00	0.00
	Total Capital Employed (Segment Assets-Segment Liabilities)	12202.30	12098.33	11855.50	12098.33

DATE: 07.08.2024
PLACE: INDORE

For and on behalf of board of directors of
MEDI-CAPS LIMITED



ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321

NOTES:

1. The above standalone and consolidated unaudited financial results for the Quarter ended June 30, 2024, were reviewed and recommended by the Audit Committee and approved by the Board of Directors in its meeting held on August 07, 2024. The above results have been reviewed by statutory Auditors of the company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, who have expressed an unmodified opinion. The Company's Management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of its affairs.
2. This statement has been prepared in accordance with the guidelines issued by the Securities Exchange Board of India (SEBI) and Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
3. The above consolidated results included the result of wholly owned subsidiary company i.e. Medgel Private Limited.
4. The Company has two reportable segments for the Consolidated Financial Statements which consists Pharma division and Real Estate division in accordance with Ind AS-108 Operating Segment and same is enclosed with this result.
5. During this quarter the Company has generated the revenue of Rs. 27.75 Lacs from sale of shops at Medi-caps Business Park.
6. The loss on a consolidated basis incurred due to lower subsidiary revenue and the sale of few shops in holding company. The sale of product of subsidiary is affected by fluctuated African market and downfall in US economy due to unstable US government and election time as well as due to continuity of USFDA warning letter matter.
7. The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or re-casted wherever found necessary.
8. The figures for the quarter ended 31st March 2024 are the balancing figures between the audited figures in respect of the full financial year and the year to date figures up to the third quarter which were subject to limited review.
9. The aforesaid Un-audited financial Results will be uploaded on the Company's website www.medicaps.com and will also be available on the websites of the Stock exchange i.e. www.bseindia.com for the benefit of shareholders and investors

DATE: 07/08/2024
PLACE: INDORE

For and on behalf of the Board of directors of
MEDICAPS LIMITED



ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321